Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-26
2007-06-26
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007940, C435S007950, C436S015000, C436S064000, C436S086000, C436S173000
Reexamination Certificate
active
10480847
ABSTRACT:
Use of calcineurin B homologous protein (CHP) from body fluids or body tissues as a marker peptide for diagnosis, for prognosis and for monitoring the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
REFERENCES:
patent: 5639617 (1997-06-01), Bohuon
patent: 5660994 (1997-08-01), Bruder-Heid et al.
patent: 198 47 690 (2000-04-01), None
patent: 0 656 121 (1998-03-01), None
patent: WO 99/37790 (1999-07-01), None
patent: WO 00/12120 (2000-03-01), None
patent: WO 00/22439 (2000-04-01), None
Wei et al. WO 00/12120 English Translation.
Biochemistry 1990 vol. 29, p. 8509 (Wells et al.) From genes to proteins structure and functions in Trends in Biotech 2000, vol. 18, p. 34 (Skolnick); (Tobias et al.) “Errors in genome annotation.” In Trends in Genetics vol. 15, p. 132 (Brenner et al.).
“The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 492-495.
“Powers and Pitfalls in Sequence Analysis” in Trend in Genetics vol. 14, p. 398 (Bork et al).; “Go hunting in sequence databases but watch out for the traps” in Trends in Genetics, vol. 12, p. 425 (Bork).
Assicot, et al., “High Serum Procalcitonin Concentrations in Patients with Sepsis and Infection,”Lancet, 341(8844):515-518, 1993.
Beishuizen et al., “Endogenous Mediators in Sepsis and Septic Shock,”Advances Clin. Chem., 33:55-131, 1999.
Calandra et al., “Protection from Septic Shock by Neutralization of Macrophage Migration Inhibitory Factor,”Nature Medicine, 6(2):164-170, 2000.
Gabay and Kushner, “Acute-Phase Proteins and Other Systemic Responses to Inflammation,”New Engl. J. Med., 340(6):448-454, 1999.
Garber, “Protein C May Be Sepsis Solution,”Nature Biotechnology, 18:917-918, 2000.
Ghillani et al., “Monoclonal Antipeptide Antibodies as Tools to Dissect Closely Related Gene Products,”J. Immunol., 141(9):3156-3163, 1988.
Ghillani et al., “Identification and Measurement of Calcitonin Precursors in Serum of Patients with Malignant Diseases,”Cancer Research, 49(23):6845-6851, 1989.
Kanazawa et al., “CYFRA 21-1. A Cytokeratin Subunit 19 Fragment, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease,”Clin. Sci., 94(5):531-539, 1998.
Klose, “Fractionated Extraction of Total Tissue Proteins from Mouse and Human for 2-D Electrophoresis,”In: Methods in Molecular Biology, vol. 112,2-D Proteame Analysis Protocols, Humana Press Inc., N.J., pp. 67-85.
Klose and Kobalz, “Two-Dimensional Electrophoresis of Proteins: An Updated Protocol and Implications for a Functional Analysis of the Genome,”Electrophoresis, 16:1034-1059, 1995.
Lin et al., “Inhibition of Calcineurin Phosphatase Activity by a Calcineurin B Homologous Protein,”J. Biol. Chem., 274(51):36125-36131, 1999.
Lingner et al., “Reverse Transcriptase Motifs in the Catalytic Subunit of Telomerase,”Science, 276:561-567, 1997.
Mann and Pandey, “Use of Mass Spectrometry-Derived Data to Annotate Nucleotide and Protein Sequence Databases,”TRENDS Biochem. Sci., 26(1):54-61, 2001.
Neubauer et al., Mass Spectrometry and EST-Database Searching Allows Characterization of the Multi-Protein Spliceosome Complex,Nature Genetics, 20:46-50, 1998.
Oczenski et al., “Procalcitonin: A New Parameter for the Diagnosis of Bacterial Infection in the Peri-Operative Period,”Eur. J. Anaesthesiol., 15:202-209, 1998.
Otto et al., “Identification of Human Myocardial Proteins Separated by Two-Dimensional Electrophoresis Using an Effective Sample Preparation for Mass Spectrometry,”Electrophoresis, 17:1643-1650, 1996.
Panacek, “Anti-TNF Strategies,”Intensive Care Med., 23:1144-1149, 1997.
Redl et al., “Procalcitonin Release Patterns in a Baboon Model of Trauma and Sepsis: Relationship to Cytokines and Neopterin,”Crit. Care Med., 28(11):3659-3663, 2000.
Redl and Schlag, “Non-Human Primate Models of Sepsis,”Sepsis, 2:243-253, 1998.
Reinhart et al., “Sepsis Und Spetischer Schcok,”Intensivmedizin, 756-760, 2001.
International Search Report for PCT/EP 02/06660, mailed Oct. 10, 2002.
Aird, “The Hematologic System as a Marker of Organ Dysfunction in Sepsis,”Mayo Clin, Proc., 78:869-881, 2003.
Carrigan et al., “Toward Resolving the Challenges of Sepsis Diagnosis,”Clin. Chem., 50(8):1301-1314, 2004.
Hotchkiss and Karl; “The Pathophysiology and Treatment of Sepsis,”N. Engl. J. Med., 348(2):138-150, 2003.
Marshall et al., “Measures, Markers, and Mediators: Toward a Staging System for Clinical Sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, Oct. 25-26, 2000,”Crit. Care Med., 31(5):1560-1567, 2003 (Abstract only).
Oberholzer et al., “Sepsis Syndromes: Understanding the Role of Innate and Acquired Immunity,”Shock, 16(2):83-96, 2001 (Abstract only).
Bergmann Andreas
Struck Joachim
Ühlein Monika
B.R.A.H.M.S Aktiengesellschaft
Cheu Jacob
Dias, Esq. Kathy Smith
Heslin Rothenberg Farley & & Mesiti P.C.
Le Long V.
LandOfFree
CHP for use as marker for sepsis-type inflammatory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CHP for use as marker for sepsis-type inflammatory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CHP for use as marker for sepsis-type inflammatory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3827926